Startup profile · funding coverage
Valar Labs
Computational histology AI predicting cancer therapy response from pathology slides.
Stage
series a
Status
private
Coverage
full
Why Valar Labs is interesting
CHAI tests like Vesta for bladder cancer turn standard H&E slides into treatment-selection signals — precision oncology without new assays.
Key facts
- Series A (May 2024): $22M co-led by a16z Bio+Health and DCVC; Pear VC participated (Business Wire)
- Seed (2022): $4M led by a16z (a16z announcement)
Investors in our directory
Funds linked from Valar Labs's profile — open a fund page for stage focus and related deal articles.
Industries
Generalist Technology
Industry hub pages are rolling out from our fund-derived baseline taxonomy.
Related funding articles
Venture Capital Tracker pieces that cover Valar Labs's financing or category context.
Last updated: 2026-07-24